Advanced Medical Solutions Group Regulatory News (AMS)

13 Jun 2006 07:02

Advanced Medical Solutions Grp PLC13 June 2006 For immediate release 13 June 2006 Advanced Medical Solutions Group plc ("AMS" or "the Company") To exhibit at Growth Company Investor Show on 21 June 2006 Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the globalmedical technology company, today announces that it will be exhibiting at theforthcoming Growth Company Investor Show to be held at the Barbican ExhibitionHalls, London, on 21 June 2006. The Company will be represented by Don Evans, Chief Executive, and ChrisMeredith, Commercial Director, on Stand No. 30. This is an opportunity forinvestors to visit the stand and talk to the Company's senior management aboutrecent events, products, market strategies and growth plans for the future. Now in its second year, the Growth Company Investor Show brings together leadingsmall and mid-cap quoted companies giving existing and potential new investorsthe opportunity to meet and network with management teams and also to attend acomprehensive seminar programme. -ENDS- For further information, please contact: Advanced Medical Solutions Group plc Tel : +44 (0) 1606 545508 Don Evans, Chief Executive Mary Tavener, Finance Director www.admedsol.com Buchanan Communications Tel: +44 (0) 20 7466 5000 Mark Court, Mary-Jane Johnson Stand No. 30 Notes to Editors: Advanced Medical Solutions is a leading company in the development andmanufacture of products for the $13 billion global woundcare market. Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions isfocused on the design, development and manufacture of innovative andtechnologically advanced products for woundcare and other medical applications. In-house natural and synthetic polymer technology is used to provide advancedwound dressings based on the moist healing principle. AMS' resources ensure aunique position as a vertically integrated 'one stop shop' to provide allcategories of moist wound healing products. The Company has the capability tomove from product design and development through to production and deliveryready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products and technology incyanoacrylate based tissue adhesives that offer benefits over sutures andstaples for closing wounds sold direct to hospitals or through distributors. AMS' technology and products currently serve the majority of the key globalmarkets and strategic partners. This information is provided by RNS The company news service from the London Stock Exchange